← Back

Outset Medical Inc

Outset Medical, Inc. is a medical technology company that develops a hemodialysis system for use in the United States. Its Tablo Hemodialysis System is a compact console featuring integrated water purification, on-demand dialysate production, and software and connectivity capabilities. The company manufactures, supports, and distributes the Tablo console, Tablo cartridge, and other consumables, and offers the Tablo Data Ecosystem, which includes the TabloHub consumer portal, the MyTablo patient portal, and the TabloDash internal data analytics platform. Formerly known as Home Dialysis Plus, Ltd., it changed its name to Outset Medical, Inc. in January 2015, was incorporated in 2003, and is headquartered in San Jose, California.

Country
Price · split & dividend adjusted
News & notes moving OM
United States
OM▼

Outset Medical reports Q2 loss of $0.80 per share, revenue beats estimates

Outset Medical posted a second-quarter loss of $0.80 per share, missing the Zacks Consensus Estimate of a loss of $0.63 and marking an earnings surprise of negative 26.98%. Revenue came in at $31.64 million, surpassing the consensus estimate by 9.84% and edging above the year-ago figure of $31.42 million. The company has not beaten consensus EPS estimates in any of the last four quarters and has topped revenue estimates only once in that span. Shares have gained about 38% year-to-date, outpacing the S&P 500's 12.8% advance. The current consensus EPS estimate stands at a loss of $0.67 on $34.9 million in revenue for the coming quarter and a loss of $2.88 on $127.5 million in revenue for the full fiscal year.
OM ▼
OM · Capital · Negative Q2 loss of $0.80 per share missed consensus estimate of $0.63 loss.
Read original ↗
Zacks Investment Research·59dRead more →
Biotech & Genomic Medicine▲

Can-Fite, SeaStar Medical, Elicio Lead Biotech Gainers on Study Updates and Revenue Growth

Can-Fite BioPharma, SeaStar Medical, and Elicio Therapeutics were among the top biotech gainers on Wednesday. Can-Fite soared over 55% after its Phase 2a pancreatic cancer study with Namodenoson met its primary safety endpoint and showed durable overall survival, prompting plans for a Phase 2b combination trial. SeaStar Medical jumped more than 30% as net revenue for its flagship QUELIMMUNE pediatric therapy rose to approximately $0.5 million in the first quarter of 2026 from $0.3 million a year earlier, with full-year 2026 product revenue expected to reach about $2 million. Elicio Therapeutics climbed over 31% following its addition to the Russell 2000 and Russell 3000 Indexes and the refinement of its Phase 3 development strategy for ELI-002, despite the Phase 2 AMPLIFY-7P trial missing its primary endpoint. Regentis Biomaterials gained more than 29% as it prepares to begin European surgeon training for its CE Mark-approved knee cartilage implant GelrinC. TransCode Therapeutics rose over 20% for a second straight day, with a Phase 2a trial of its metastatic cancer therapy TTX-MC138 underway and preliminary results expected in the fourth quarter of 2026. Outset Medical advanced over 18% after reporting first-quarter 2026 revenue of $27.9 million and projecting full-year revenue between $125 million and $130 million.
ELTX ▲ICU ▲OM ▲RNAZ ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics Competition
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Demand
ELTX · Capital · Positive Added to Russell 2000 and Russell 3000 Indexes, and refined Phase 3 strategy for ELI-002
ICU · Demand · Positive Net revenue for QUELIMMUNE rose to ~$0.5M in Q1 2026 from $0.3M a year earlier
OM · Capital · Positive Reported Q1 2026 revenue of $27.9M and projected full-year revenue between $125M and $130M
RNAZ · Technology · Positive Phase 2a trial of TTX-MC138 underway with preliminary results expected in Q4 2026
Regentis Biomaterials · Technology · Positive Preparing to begin European surgeon training for CE Mark-approved knee cartilage implant GelrinC
Read original ↗
RTTNews·95dRead more →
© 2026 MarketDXAsset